TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Johnson & Johnson has introduced RYBREVANT® as a groundbreaking therapy for the initial treatment of individuals diagnosed with non-small cell lung cancer...
Iovance Biotherapeutics has developed first-of-its-kind AMTAGVI™ cell therapy for a solid tumour cancer and first treatment option for advanced melanoma....
Bayer has introduced a groundbreaking therapy named BAY 2927088 for addressing adult patients afflicted with unresectable or metastatic non-small cell lung cancer...
Nuvalent has developed NVL-520, a new treatment for patients with ROS1-positive metastatic non-small cell lung cancer who have previously undergone treatment with two or more ROS1 tyrosine kinase inhibitors...
Biogen has developed SKYCLARYS®, marking a significant breakthrough as the inaugural therapeutic option for addressing Friedreich’s ataxia in adults and adolescents aged 16 years and older....
Chugai Pharmaceutical has developed a groundbreaking treatment named crovalimab, a humanised monoclonal antibody targeting complement C5, designed particularly for adults and adolescents...
Takeda has discovered first-of-its-kind EOHILIA , the only FDA-approved oral therapy tailored for individuals aged 11 and above grappling with eosinophilic oesophagitis...
Regeneron Pharmaceuticals has introduced Dupixent® for treating paediatric patients aged 1 to 11 years with eosinophilic oesophagitis, weighing at least 15 kg. Dupixent, a fully human monoclonal antibody...
Alector has introduced atozinemab, a groundbreaking investigational human monoclonal antibody crafted to obstruct sortilin, thereby boosting progranulin levels, offering promise in treating frontotemporal dementia with a progranulin gene mutation...
RadioMedix and Orano Moed have jointly developed a groundbreaking treatment named AlphaMedix™ for adults with unresectable or metastatic gastroenteropancreatic neuroendocrine tumours...